Hemovent receives government grant to fast-forward development of its next-gen artificial lung Technologies
The Hemovent GmbH, an emerging medical device company, has been awarded participation in a grant totaling $810,000 from the German government to fast-forward development of its novel and portable artificial lung technologies, designed for a wide range of applications from Extracorporeal CO2 Removal (ECCO2R) to ExtraCorporeal Life Support (ECLS).
These types of applications are referred to as Extracorporeal Membrane Oxygenation (ECMO), which means the establishment of an artificial external blood circuit with a portable pump and gas exchanger system in order to support the lung function only or even establish a full cardiopulmonary bypass. ECMO as a temporary “artificial lung” either provides respiratory support to patients whose lungs are so damaged that they cannot perform their function, or as a temporary “life support system” and takes over the heart function in case of an acute heart failure. Both solutions allow physicians time to address the underlying problems that caused the failure.
Hemovent GmbH has developed the world’s smallest and first self-contained fully portable artificial lungs for Extra Corporeal Membrane Oxygenation (ECMO) / ExtraCorporeal Life Support (ECLS) applications designed to support or replace heart and lung function in the event of cardiac and/or respiratory failure.
For further Information see here.